M11.25 Other chondrocalcinosis, hip

Name of the Condition

• Other chondrocalcinosis, hip

Summary

Other chondrocalcinosis, hip refers to the deposition of calcium-containing crystals in the hip joint tissues, excluding calcium pyrophosphate dihydrate (CPPD) or hydroxyapatite. This condition causes joint inflammation, pain, and potential structural damage, often mimicking other arthritic diseases. Diagnosis typically requires identifying the specific crystal type through joint fluid analysis or tissue sampling.

Causes

Other chondrocalcinosis, hip is caused by the deposition of non-CPPD, non-hydroxyapatite calcium crystals (e.g., calcium oxalate, calcium phosphate) in the hip’s cartilage, synovium, or surrounding tissues. The exact triggers vary but may include metabolic imbalances, genetic factors, or underlying systemic conditions. Crystal formation provokes an inflammatory response, leading to joint symptoms.

Risk Factors

• Metabolic disorders (e.g., hyperoxaluria, hypophosphatasia).
• Chronic kidney disease or dialysis.
• Genetic predisposition to crystal formation.
• Exposure to certain medications or toxins.
• Hip trauma or surgery.

Symptoms

• Hip pain, swelling, and stiffness.
• Warmth and redness over the affected joint.
• Reduced range of motion.
• Recurrent episodes of inflammation.
• Systemic symptoms (e.g., fever) in severe cases.

Diagnosis

Diagnosis involves joint aspiration to analyze synovial fluid for crystal type, imaging (e.g., X-ray, MRI) to assess joint damage, and clinical evaluation of symptoms. Tissue sampling may be used if crystal identification is unclear. Exclusion of CPPD or hydroxyapatite crystals is critical for confirmation.

Treatment Options

Treatment focuses on reducing inflammation and managing pain, often with nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids. Physical therapy may help maintain mobility. Underlying metabolic or systemic conditions are addressed to prevent further crystal deposition. Surgical intervention is rare but may be considered for severe joint damage.

Prognosis and Follow-Up

Prognosis depends on the extent of joint damage and response to treatment. Early intervention can mitigate symptoms, but chronic cases may lead to progressive joint dysfunction. Regular follow-up with imaging and clinical assessments is recommended to monitor joint health and adjust treatment as needed.

Complications

• Chronic joint pain and stiffness.
• Progressive cartilage or bone damage.
• Reduced mobility or disability.
• Recurrent inflammatory episodes.
• Secondary osteoarthritis.

Lifestyle & Prevention

• Maintain a balanced diet to support metabolic health.
• Stay hydrated, especially if at risk for crystal formation.
• Avoid excessive joint stress or trauma.
• Manage underlying conditions (e.g., kidney disease) with medical guidance.
• Engage in low-impact exercise to preserve joint function.

When to Seek Professional Help

Seek care if hip pain is severe, persistent, or accompanied by swelling, redness, or fever. Prompt evaluation is important if symptoms worsen or interfere with daily activities, as early treatment may prevent long-term damage.

Tips for Medical Coders

Document the specific hip joint involvement and crystal type (if identified) to support the M11.25 code. Include clinical details (e.g., imaging findings, synovial fluid analysis) to confirm the diagnosis and differentiate from other arthritic conditions. Ensure documentation aligns with the exclusion of CPPD or hydroxyapatite crystals.